NAMPT Inhibitor Market

NAMPT Inhibitor Market, Distribution by Type of Molecule, Therapeutic Area, Indication, Route of Administration, Line of Treatment and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2040

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    89

  • Slides
    141

  • View Count
    7594

The NAMPT inhibitor developed during our research can be used to target inflammatory disorders, metabolic disorders and oncological disorders. Importantly, our compound has been studied in the preclinical stages, for the treatment of pancreatic cancer

-- Former Research Associate, an India-based mid-sized company

NAMPT Inhibitor Market Overview

The NAMPT inhibitor market is expected to grow at compounded annual growth rate (CAGR) of 15% during the forecast period, driven by growing burden of cancer patients. Further, according to a study published in American Cancer Society Journal, by 2040, the number of cancer cases is projected to reach over 28 million, indicating a cumulative growth of nearly 47%, since 2020. The continuous growth in the number of cancer patients imposes a huge burden, in terms of finances as well as resources, on  the overall healthcare system. In this context, it is worth mentioning that the annual expenditure associated with cancer care is more than USD 200 billion, in the US alone. Given the fact that majority of the current treatment options for cancer have proven to be inadequate, especially for late-stage cancers, there is a high demand for highly effective therapeutics. Over time, many research studies have demonstrated that NAMPT (Nicotinamide Phosphoribosyl Transferase) can interfere with the metabolism of NAD+, which is known to be the fuel for tumor cells; this notion has encouraged several researchers to conduct extensive studies for the development of novel and efficacious drug candidates, such as NAMPT inhibitors.

This image presents the pipeline review of NAMPT Inhibitors. A large share of ongoing clinical studies related to NAMPT inhibitors are evaluating small molecules, primarily as monotherapies This image highlights competitive analysis of players engaged in the domain of NAMPT Inhibitors Market. In order to gain an edge in this competitive industry, drug developers are continuously upgrading their existing pipeline, by entering into strategic collaborations, seeking investments and expanding their intellectual capital This image provides information on funding and investments received by the players engaged in NAMPT Inhibitors Market. Having realized the opportunity associated with this lucrative segment, several investors have collectively invested multi-million dollars, across nearly 30 funding instances

NAMPT inhibitors are being evaluated to target a wide range of indications, primarily focusing on oncological disorders. Given the encouraging research outcomes, the NAMPT inhibitor market has attracted the attention of many private and public investors who have made investments worth more than USD 650 million, since 2018. Driven by the increasing R&D activity, promising clinical data and financial support from investors, the NAMPT inhibitor market is anticipated to witness a commendable market growth during the forecast period.

Key Companies in NAMPT Inhibitor Market 

Examples of key companies engaged in NAMPT inhibitor market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Antengene Therapeutics, Aqualung Therapeutics, Karyopharm Therapeutics, OncoTartis and Onxeo. This market research report includes an easily searchable excel database of all the companies developing NAMPT inhibitor, worldwide.

This image presents review of scientific articles related to NAMPT Inhibitors. The rising number of scientific articles being published in this domain is indicative of the substantial efforts undertaken by stakeholders to develop novel NAMPT inhibitors This image provides information on the global events undertaken by the players engaged in NAMPT Inhibitors Market. Over the years, several events, including conferences, expeditions, forums and summits, focused on NAMPT inhibitors have been conducted across the globe This image highlights the prevalent and emerging trends related to NAMPT inhibitors as represented on the social media platform. The growing optimism of industry stakeholders is indicated by the significant increase in the number of tweets on the social medial platform, Twitter, in the past decade

Recent Developments in NAMPT Inhibitor Market:

Several recent developments have taken place in the field of NAMPT inhibitor market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In September 2022, Aqualung Therapeutics announced the FDA clearance of investigational new drug (IND) application for ALT-100, the first humanized mAb therapy, that targets the eNAMPT protein which plays a pivotal role in regulating inflammation and fibrosis.

Scope of the Report

The “NAMPT Inhibitor Market, Distribution by Type of Molecule (Small Molecules and Biologics), Therapeutic Area (Oncological and Respiratory Disorders), Indication (Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Respiratory Distress Syndrome, and Acute Myeloid Leukemia), Route of Administration (Oral and Intravenous), Line of Treatment (1st Line and 2nd Line), and Key Geographical Regions (North America, Europe, Asia and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities for NAMPT inhibitors in the healthcare domain, during the forecast period. The market research report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market space.

This image provides an in-depth analysis focused on NAMPT inhibitors that failed to progress to later stages of clinical development. Lack of efficacy, toxicity, thrombocytopenia and scarce funding are among the key reasons that have led to the discontinuation of studies sponsored by various industry and non-industry players This image highlights competitive strategies that can be implemented by drug developers engaged in this domain, to expedite the FDA approval process for their proprietary products. In recent years, companies have undertaken several initiatives, specific to their drug candidates, to overcome the challenges associated with the clinical development of NAMPT inhibitors This image provides information on the current and future market trends and potential growth of NAMPT Inhibitors Market. Considering the growing innovation related to stent materials and various drug combinations that can be employed to manufacture drug eluting stents, the demand for such devices is anticipated to rise in the future

 

Amongst other elements, the market report includes:

 

  • A brief introduction to important concepts related to NAMPT inhibitors, featuring information on key historical events, key indications targeted by such therapeutics, potential concerns associated with their use and mechanism of action. This chapter further features details related to the recent advancements that have been made in the NAMPT inhibitor market.
  • A detailed overview of the current market landscape of NAMPT targeting drug candidates that are currently being researched in pre-clinical and clinical studies, featuring an elaborate analysis of such therapies based on several relevant parameters, such as phase of development (preclinical, phase I, phase I/II and phase II), type of molecule (small molecules and biologics), route of administration (oral and intravenous), target indication (acute myeloid leukemia, acute respiratory distress syndrome, hodgkin lymphoma, and non-hodgkin lymphoma), line of treatment (1st line and 2nd line) and type of therapy (monotherapy and combination therapy). 
  • An elaborate analysis of recent partnerships and collaborations that have been inked by several stakeholders engaged in the domain of NAMPT inhibitors since 2022, including a brief description of the various partnership models adopted (including product development and commercialization agreement, product development, manufacturing and commercialization agreement, mergers and research and development agreement).
  • An insightful analysis of recent funding instances that have been reported by several players engaged in the NAMPT inhibitor market, including details on the year of funding, amount received and type of funding (awards / grants, venture series, initial public offering, secondary offerings, debt financing and other equity).
  • An in-depth analysis on various grants, since the year 2022, received by players engaged in this field based on year of award, amount awarded, funding institute, activity code, focus area, recipient organizations, support period, type of grant application, and prominent program officers.
  • An insightful company competitiveness analysis of NAMPT inhibitor targeting therapy developers, based on several relevant parameters, such as the firm’s portfolio strength (taking into consideration number of drugs in pipeline, phase of development and type of molecule), partnership strength (in terms of the number of partnerships established and partnership year) and funding strength (in terms of number of funding instances, amount of funding, year of funding, type of funding and number of lead investors).
  • Elaborate profiles of prominent players that are engaged in the development of NAMPT inhibitors, featuring a brief overview of the company, along with information on financials, product portfolio, patent portfolio, recent developments and an informed future outlook.
  • A detailed analysis of several peer-reviewed, scientific articles related to research on NAMPT inhibitors, over last 12 years, based on several relevant parameters, such as year of publication, type of publication and popular keywords.
  • An analysis of the global events attended by industry players, based on several relevant parameters, such as year of event, event platform, type of event, leading presenters (in terms of number of participations) and leading players (in terms of number of participations).
  • An analysis of prevalent and emerging trends related to NAMPT inhibitors as represented on the social media platform, Twitter, based on several relevant parameters, such as year of tweet, top users and emerging focus areas.
  • An in-depth analysis focused on NAMPT inhibitors that failed to progress to later stages of clinical development, based on various relevant parameters, such as phase of discontinuation, target indication, route of administration and type of molecule.
  • A proprietary analysis on various competitive strategies that can be implemented by drug developers engaged in NAMPT inhibitor market, to expedite the FDA approval process for their proprietary products; it includes information on several relevant parameters, such as clinical evidence, awards / grants, research findings, partnerships, other financial support received and others.

The key objective of NAMPT inhibitor market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for NAMPT inhibitor market during the forecast period. Based on several relevant parameters, such as target patient population, likely launch year of therapy candidates, approval timeline of drugs, likely price points and expected rates of adoption, across various geographical regions. The market report also features the likely distribution of the current and forecasted opportunity related to NAMPT inhibitor market across type of molecule (small molecules and biologics), therapeutic area (oncological and respiratory disorders), indication (non-hodgkin lymphoma, hodgkin lymphoma, acute respiratory distress syndrome, and acute myeloid leukemia), route of administration (oral and intravenous), line of treatment (1st line and 2nd line), and key geographical regions (North America, Europe, Asia and Rest of the World).

Frequently Asked Questions

Question 1: What are NAMPT inhibitors?

Answer: NAMPT inhibitors are a group of diverse pharmaceutical entities, having significant anti-tumor efficacy and the potential to treat cancer.

Question 2: What is the projected market growth of the NAMPT inhibitor market?

Answer: Although no NAMPT inhibitor is approved to date, the NAMPT inhibitor market is expected to grow at compounded annual growth rate (CAGR) of 15% during the forecast period, which will be driven by the approvals later in the forecast period.

Question 3: Who are the leading companies in the NAMPT inhibitor market?

Answer: Examples of key companies engaged in NAMPT inhibitor market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Antengene Therapeutics, Aqualung Therapeutics, Karyopharm Therapeutics, OncoTartis and Onxeo.

Question 4: How much investment has been made in the NAMPT inhibitor market by key industry stakeholders?

Answer: Since 2018, more than $650 billion has been invested in the NAMPT inhibitor market by various private and public investors engaged in this market.

Question 5: Which partnership model is most preferred by the companies engaged in NAMPT inhibitor market?

Answer: Currently, 50% of the deals inked in the NAMPT inhibitor market are for product development and commercialization.

Question 6: How many articles have been published in the NAMPT inhibitor market?

Answer: Since 2010, close to 70 articles have been published in the NAMPT inhibitor market, highlighting the ongoing research in the field.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com